RE:New Press Release - Microbix Reports Results for Q3 Fiscal 2023 Can't say the inventory write-off is surprising, the DxTm line seems to be dead regardless of their optimism that they can salvage something from it and all their rosy predictions about non COVID applications. They should just put this behind them, government is rarely a good partner.
QAPs sales disappointing but also not surprising due to lack of any new partnership announcements. Q4 is halfway done now so I sure hope they've been selling and not just talking despite the lack of formal partnerships. They need to deliver significant QAPs growth in Q4 and Q1 24 or the market will think this is going the way of DxTm.
Antigen sales have rebounded nicely. Kinlytic obviously huge potential and the payment thankfully took some of the edge of another poor quarter. Finishing the upgrades to enable strong growth another accomplishment, so the obstacles to fast and explosive growth have been removed. No more excuses, Management needs to deliver now. Haven't lost faith but not putting lip stick on this pig either.